CD22 and anemia: Among the five patients treated with CD19/CD22 BS Loop CAR-T cells, the main adverse reactions included fever and hematologic toxicity; three patients presented with low-grade fever, one patient developed rash, four patients had thrombocytopenia, and all five patients experienced neutropenia and developed anemia (Supplementary Table S2).